Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC
Robert A Figlin
Correspondence Division of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Care Center, 1500 East Duarte Road, Duarte, CA 91010, USA
Email rfiglin@coh.org
Mammalian target of rapamycin (mTOR) is an important and clinically relevant therapeutic target. Temsirolimus has significantly improved overall survival rates in patients with advanced renal cell carcinoma, thereby validating the importance of mTOR in the natural history of this disease. This Review discusses the clinical development of temsirolimus, its novel mechanism of action, and the investigational strategies for targeting mTOR in other tumor types.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$32 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.